VIRVir Biotechnology, Inc.
The schedule
- Thu15Oct
Anticipated strategic update on VIR-2482 after the inconclusive April Phase 2 efficacy readout.
- Tue15Dec
Expected initial combo data for the prostate cancer asset VIR-5500 under the Astellas partnership.
- Wed3Feb
Q3 2026 earnings release, providing an update on clinical progress and pipeline liquidity.
- Wed5May
Fiscal Q4 2026 results and 2027 pipeline guidance.
- Wed4Aug
Q1 2027 financial results and operational roadmap.
Past
- Wed5Aug
Vir reports its Q2 2026 financials, with intense focus on operating cash burn following the recent $200M dilutive raise.
- Thu7May
Actual outcome: Mixed · $9.29 at outcome
Vir Biotechnology reported Q1 EPS that exactly met analyst expectations at -$0.85, while highlighting positive Phase 1 data for VIR-5500 and the execution of its global oncology agreement with Astellas. With no major financial surprises to shift the fundamental narrative, the market reaction was muted, leaving the stock flat and trading squarely between the bull and bear targets.
Vir Biotechnology reported Q1 EPS that exactly met analyst expectations at -$0.85, while highlighting positive Phase 1 data for VIR-5500 and the execution of its global oncology agreement with Astellas. With no major financial surprises to shift the fundamental narrative, the market reaction was muted, leaving the stock flat and trading squarely between the bull and bear targets.
- Wed1Apr
Actual outcome: Mixed · $9.06 at outcome
Vir Biotechnology released Phase 2 data for VIR-2482 that met primary safety endpoints but showed inconclusive efficacy in preventing symptomatic Influenza A. Because the results neither confirmed a clear path to commercialization nor outright invalidated the program, the stock traded flat as investors awaited further clinical clarity.
Vir Biotechnology released Phase 2 data for VIR-2482 that met primary safety endpoints but showed inconclusive efficacy in preventing symptomatic Influenza A. Because the results neither confirmed a clear path to commercialization nor outright invalidated the program, the stock traded flat as investors awaited further clinical clarity.
- Wed25Feb
Actual outcome: Bull · $9.09 at outcome
Vir significantly beat Q4 revenue estimates and announced a transformative $1.7 billion strategic partnership with Astellas for its prostate cancer candidate, VIR-5500, alongside positive Phase 1 clinical data. While the company executed a $200 million dilutive share offering immediately following the news, the market prioritized the validated oncology pipeline and strengthened balance sheet, keeping the stock well above the bull target.
Vir significantly beat Q4 revenue estimates and announced a transformative $1.7 billion strategic partnership with Astellas for its prostate cancer candidate, VIR-5500, alongside positive Phase 1 clinical data. While the company executed a $200 million dilutive share offering immediately following the news, the market prioritized the validated oncology pipeline and strengthened balance sheet, keeping the stock well above the bull target.
